Targeting the pregnane X receptor in liver injury (review)

Tao Li¹, Ruth T. Yu¹, Annette R. Atkins¹, Michael Downes¹, Robert H. Tukey², and Ronald M. Evans¹

¹Howard Hughes Medical Institute, Gene Expression Laboratory, The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037
²Laboratory of Environmental Toxicity, Department of Pharmacology, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA, 92093

Abstract

Introduction—The nuclear receptor pregnane X receptor (PXR) is a well-characterized hepatic xenobiotic sensor whose activation by chemically diverse compounds results in the induction of drug clearance pathways that rid the body of potentially toxic substances, thus conferring protection from foreign chemicals and endobiotics.

Area covered—PXR activities are implicated in drug-drug interactions and endocrine disruption. Recent evidence supports a hepatoprotective role for PXR in chronic liver injury, inhibiting liver inflammation through suppression of the NF-κB pathway. However, PXR-mediated induction of CYP3A enhances APAP-induced acute liver injury by generating toxic metabolites. While these observations implicate PXR as a therapeutic target for liver injury, they also caution against PXR activation by pharmaceutical drugs.

Expert opinion—While evidence of PXR involvement in acute and chronic liver injuries identifies it as a possible therapeutic target, it raises additional concerns for all drug candidates. The in vitro and in vivo tests for human PXR activation should be incorporated into the FDA regulations for therapeutic drug approval to identify potential liver toxicities. In addition, PXR pharmacogenetic studies will facilitate the prediction of patient-specific drug reactivities and associated liver disorders.

Keywords

PXR; liver injury; xenobiotic; nuclear receptor; drug target

1. Nuclear receptor superfamily

Nuclear receptors are members of a superfamily of ligand-inducible transcription factors mediating responses to endogenous steroids, retinoids and thyroid hormones. They regulate specific target genes involved in metabolism, development, reproduction and other physiological processes. The cloning of the first nuclear receptor, the human glucocorticoid receptor (hGR) in 1985, facilitated the identification of multiple additional family members by low stringency hybridization screening of cDNA libraries such as the estrogen receptor (ER), progesterone receptor (PR), thyroid hormone receptor (TR), retinoic acid receptor (RAR), Vitamin D receptor (VDR), mineralocorticoid receptor (MR) and androgen receptor (AR). The nuclear receptor family is comprised of 48 members in
humans and includes 36 orphan nuclear receptors, receptors which lack identified physiological ligands 10.

The classical steroid hormone receptors such as GR, MR, PR, AR and ER form functional homodimers upon ligand binding that recognize hormone response elements (HREs) on target DNA to control gene expression. GR, MR, PR, and AR bind inverted repeats of the half site AGAACA (GRE) while ER binds an inverted repeat of the half site AGGTCA (ERE). The 36 orphan receptors bind to a half site either as a monomer, dimer, or heterodimer with the retinoid X receptor (RXR). Biological roles for the orphan receptors, particularly those which heterodimerize with RXR, have been elucidated through the identification of functional response elements and, ultimately, the discovery of relevant endogenous and synthetic ligands. Further understanding has been achieved by creating knock-out mouse models. It is now known that many orphan receptors act as low affinity sensors for abundant dietary lipids, contrasting with the high affinity steroid receptors have for low abundant hormones. For example, the liver X receptors (LXRs), peroxisome proliferator activated receptors (PPARs) and farnesoid X receptor (FXR) have been identified as sensors for cholesterol, fatty acids, and bile acids, respectively, and shown to cooperatively regulate lipid homeostasis (reviewed in 11).

2. PXR modulates hepatic drug metabolism

In the hepatic drug clearance system, Phase I enzymes, especially members of the cytochrome P450 (CYP) 1-4 families, play important roles in xenobiotic detoxification and survival of organisms 12. Among them, the human CYP3A and CYP2B isoenzymes are involved in the metabolism of a large portion of clinical drugs (reviewed in 13). One important characteristic of these CYP enzymes is their substrate inducibility, which allows production of these proteins to be tailored to meet requirements. For example, CYP3A is induced upon treatment with the antibiotic rifampicin14, while CYP2B production is increased by the treatment with the anti-epileptic drug phenobarbital (PB) in humans 15 and the planar hydrocarbon 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP) in mice 16. In the early 1990s, researchers found that the Aryl hydrocarbon receptor (AhR) regulates transcriptional activation of the CYP1A genes 17, however, the mechanism of CYP gene induction by xenobiotics was not clear until pregnane X receptor (PXR) and constitutive androstane receptor (CAR) were defined as xenobiotic receptors.

2.1 PXR identified as a xenobiotic receptor

Pregnan X receptor (PXR), also known as the steroid and xenobiotic sensing nuclear receptor (SRX) and NR1I2, was originally identified in mice and found to be activated by naturally occurring steroids such as pregnenolone and progesterone, as well as by both synthetic glucocorticoid agonists and antagonists18-20. In addition, PXR was shown to bind to the CYP3A2 promoter and activate transcription in response to potent CYP3A2 inducers 18. This unusual response profile of PXR offered a possible explanation for the behavior of catatotic compounds, compounds that induce their own catabolism, through the induction of CYP3A genes 2, 21, 2223.
Evidence supporting PXR as a xenobiotic receptor regulating CYP3A’s expression emerged rapidly. Both PXR and CYP3As are highly expressed in the liver and intestine, the major sites of drug clearance. PXR and its heterodimeric partner RXR, bind to a DR3 (direct repeats of AGGTCA or closely related sequences with a spacing of 3 nucleotides) or ER6 (everted repeats spaced by 6 nucleotides) sites in the CYP3A promoter. The binding of numerous structurally unrelated drugs to PXR, including those known to induce CYP3A expression, was found to dissociate co-repressor molecules such as the silencing mediator for retinoid and thyroid hormone receptor (SMRT) and the nuclear receptor co-repressor (NCoR) from PXR. This is followed by simultaneous recruitment of co-activator molecules, including members of the p160 family (SRC-1, GRIP and ACTR), RIP140 and PBP (DRIP205 or TRAP220). PXR null mice are both viable and fertile, indicating that in the absence of toxic insults the xenobiotic response is not required. However, PXR null mice completely lack inducibility of CYP3A by PCN or PCN-mediated induction of drug resistance. Together these observations clearly establish PXR as the central mediator of CYP3A induction.

2.2 Human ortholog of PXR

The human homologue of PXR (hPXR) was first isolated as the steroid and xenobiotic receptor (SXR) and the pregnane-activated receptor (PAR). Notably, the PXR ligand binding domain (LBD) from different species is considerably divergent. Within the LBD, the amino acid identity of human PXR with mouse PXR is only 76%, whereas the DNA-binding domain is highly conserved (96% identity). Thus the species-specificity of the induction of CYP3A enzymes might be due to the pharmacological distinction of human and rodent PXRs. For example, corticosterone and rifampicin are potent hPXR but poor mPXR activators. In contrast, PCN and dexamethasone are strong mPXR but poor hPXR activators. Despite their differences in pharmacology, the two receptors appear to act through a common metabolic pathway. Thus, the structural and pharmacological differences between human and mouse PXRs may reflect differences in rodent and primate diets and the need to respond to a different set of xenobiotics (for review, see 2). For decades, rodent models have been standard components in the assessment of potential toxicities in the development of candidate human drugs. However, the reliability of rodents as predictors of the human xenobiotic response is compromised by the species variation. Xie et al. created a humanized PXR mouse model that responded only to human-specific inducers such as rifampicin but not PCN. The xenobiotic response in this mouse model offers a standardized in vivo system for predicting potential human drug-drug interactions and is beneficial for development of new therapeutic drugs. Cultured human primary hepatocytes are valuable alternative tools, but are compromised by inter-individual variability, limited and unpredictable availability as well as high cost. Thus, the generation of the humanized PXR mice represented a major step toward generating a standardized humanized toxicological model. For review, see 13, 29.

2.3 Diversity of PXR modulators

As a xenobiotic receptor, PXR binds a highly diverse range of structurally unrelated chemicals. In fact, X-ray crystal structures of the PXR LBD have revealed that its ligand-binding pocket is relatively large compared to most other nuclear receptors, and can even
accommodate a single hydrophobic ligand in multiple configurations. Such molecular plasticity in ligand recognition is consistent with the low substrate specificity of xenobiotic enzymes. As a result, PXR activators include antibiotics such as rifampicin, cholesterol lowering drugs such as SR12813 and statins, antidepressants like the active component of St. John's wort hyperforin, the anti-neoplastic drug paclitaxel, the anti-mycotic clotrimazole (reviewed in ), bisphenol A, organochlorine pesticides such as chlordane, Cafestol, dieldrin and endosulfan. Other environmental contaminants including endocrine disrupting chemicals such as nonylphenol and phthalic acid, nonplanar polychlorinated biphenyls (PCBs) and organochloride pesticides such as trans-nonachlor and chlordane have all been shown to activate mouse PXR. With relevance to endocrine disruption, human PXR is also activated by numerous endobiotics including bile acids, corticosterone and estradiol as well as other estrogenic chemicals including diethylstilbestrol, and the phytoestrogen coumestrol. In addition to its activators, there are also a number of PXR antagonistic ligands. For example, ecteinascidin-734 blocks PXR-mediated induction of CYP3A, and arsenite inhibits both untreated and rifampicin induced CYP3A transcription in primary human hepatocytes by decreasing the activity of PXR, as well as expression of its heterodimeric nuclear receptor partner RXR. Thus, in principle, it should be possible to design specific drugs which selectively inhibit or promote the xenobiotic response.

3. PXR plays roles in chronic liver disease

Activation of PXR has been shown to have anti-fibrotic effects in a carbon tetrachloride-induced liver fibrogenesis model. In addition, the PXR activator rifampin has been shown to reduce pruritus associated with primary biliary cirrhosis in humans (PBC), although the mechanism of action was unclear. However, recent work has suggested that the anti-inflammatory actions of PXR agonists such as cyclosporine A are due to inhibition of NF-kB activity. Furthermore, the PXR activator clotrimazole was protective in an ischemia-reperfusion liver injury model in rats. As PXR activation promotes hepatocyte growth, is anti-fibrogenic, and anti-inflammatory, PXR activators may be better drugs for the treatment of chronic inflammatory liver fibrosis compared to other non-PXR activating drugs such as Tacrolimus (FK-506).

In addition to environmental toxins, our body is continuously exposed to a variety of endogenous chemicals. For example, the intrahepatic retention of cytotoxic bile acids (BAs) results in cholestasis, which is a very common type of liver injury. Farnesoid X receptor (FXR) plays a central role in regulating BA homeostasis and is a promising drug target for cholestatic liver injury. In addition to FXR, the xenobiotic nuclear receptors PXR and CAR also regulate BA homeostasis through sensing toxic by-products. For reviews, see . Lithocholic acid (LCA), a hydrophobic secondary bile acid is primarily formed in the intestine and known to cause chronic cholestatic liver disease. Staudinger et al. et al. first showed that PXR protects against liver toxicity by inducing the expression of CYP3A subfamily members in response to elevated LCA levels, resulting in hydroxylation of LCA that facilitates its excretion. Three lines of evidence support this notion. First, LCA and its direct metabolite 3-keto LCA directly bind to and activate PXR. Second, in vivo activation of PXR by administration of PCN or by expression of a constitutively active form of PXR in the liver of transgenic mice results in marked resistance to LCA toxicity in
rodents. Finally, as stated above, the potent CYP3A inducer and agonist for human PXR, rifampicin, has been reported to be effective in treating pruritus associated with chronic cholestasis. Detoxification of LCA by PXR appears to be mediated by the combined induction of CYP3A and the cytosolic sulfotransferase ST2A, both of which convert LCA to non-toxic metabolites. Thus, the drug clearance pathway regulated by PXR can be utilized to detoxify endogenously produced toxins. The reported ability of PXR to regulate inducible nitric oxide synthase (iNOS) gene expression has been proposed as a possible mechanism for the anti-inflammatory effects of steroids and xenobiotics.

PXR activation was also found to be protective in the bile duct ligation (BDL) model of cholestasis, through its regulation of cholesterol metabolism, bile acid synthesis, and multiple detoxification pathways. The marked increase in Cyp3a11 and Mrp3/4 hepatic expression levels in BDL mice suggest that PXR plays a protective role in cholestatic liver injury by increasing hydroxylation and efflux of toxic bile acids from hepatocytes into blood. Hepatic damage from bile acid accumulation was increased in PXR null mice, which suggests its potential role as a therapeutic target for the treatment of cholestasis and lipid disorders.

4. PXR – a double-edged sword in acute liver injury

Acute liver injury (ALI) refers to rapid degeneration of hepatic function in patients without known prior liver disease. When ALI becomes severe with impaired liver synthetic function, specifically coagulopathy and mental status changes (encephalopathy), it causes acute liver failure (ALF), which includes fulminant hepatic failure (FHF) and subfulminant hepatic failure (or late-onset hepatic failure). These ALF patients often present with the additional problems of confusion or coma (encephalopathy) and bruising or bleeding (coagulopathy). It was reported that up to 80% of people with fulminant hepatitis die within days to weeks. In the U.S., acetaminophen (Tylenol, or APAP) is the most common cause of ALF. Other causes of ALF include idiosyncratic reaction to medication (e.g. tetracycline, troglitazone), excessive alcohol intake, viral hepatitis, and acute fatty liver of pregnancy.

PXR activation and CYP3A induction have been shown to enhance APAP induced liver injury. APAP overdose triggers liver toxicities through the reactive metabolite, N-acetyl-p-benzoquinone imine (NAPQI), which is generated from APAP oxidized by hepatic CYP2E1, CYP1A2, and CYP3A. PCN treated mice or rifampin treated humanized mice exhibit high sensitivity to APAP liver toxicity through the induction of the CYP3A subfamily. Furthermore, Polyinosinic-polycytidylic acid (polyI:C), which is known as a PXR suppressor /antagonist, suppresses APAP-induced hepatotoxicity, suggesting that PXR antagonists with less side-effects might help reduce APAP-induced liver toxicity.

Wang et al. recently showed that lipopolysaccharide (LPS)/D-galactosamine (GalN)-treated PXR-null mice had a greater degree of acute liver injury compared to wild type mice. The elevated alanine aminotransferase (ALT), hepatocyte apoptosis, necrosis, and hemorrhagic liver injury in PXR null mice may be due to deregulated MAP kinase activation and delayed Jak2/Stat3 activation, which lead to a compromise in defence mechanisms that involve Bcl-xl, HO-1, and autophagy-mediated pathways.
5. PXR gene polymorphism affects liver injury

The antibiotic flucloxacillin functions as a PXR agonist to induce the expression of CYP3A4 and CYP2C9 genes, and a PXR polymorphism (rs3814055; C-25385T) has been associated with an increased risk of drug induced liver injury. The cause of potentiation of the risk is unclear, however, the C-25385T homozygotes have significantly less basal PXR expression and thus less CYP3A induction, which may slow down the flucloxacillin disposition in these genotypes. In addition, it has been suggested that the PXR polymorphisms (rs7643645 and rs2461823) may contribute to disease severity in nonalcoholic fatty liver disease (NAFLD) by influencing the individual's susceptibility to progress to more severe stages of the disease.

6. Summary

PXR coordinately regulates a large number of genes involved in all stages of xenobiotic metabolism including cytochrome P450 subfamilies (CYP2C, CYP1A, CYP1B, CYP2A and CYP4F), and other Phase I reductases and hydrolases (carboxylesterase, monoamine oxidase, catalase and flavin-containing monoxygenases (FMO)), Phase II conjugating enzymes which solubilize hydrophobic compounds in preparation for clearance (UDP-glucuronosyltransferase (UGT), cytosolic sulfotransferase (SULT) and GST), and Phase III membrane-bound transporters which act as efflux pumps to clear drugs and drug conjugates (MDR1 and MRP2) (Figure 1) (reviewed in 21, also see 25, 64, 65, 66). In combination with the constitutive androstane receptor (CAR, NR1I3A), PXR regulates the expression of the major hepatic Phase I enzymes responsible for clinical drug clearance, the CYP2Bs and 3As. Indeed, analysis of the promoter regions and identification of receptor binding sites of PXR/CAR target genes reveal that both PXR and CAR can adaptively bind to common response elements. In addition to CYP3A, CAR has also been shown to regulate a similar array of xenobiotic genes including several CYP enzymes, aldehyde dehydrogenase, esterase, FMO, methyl transferase, GST, SULT, UGT, and MRP2 as well as iNOS. The ability of the xenobiotic receptors to respond to a numerous yet overlapping set of drugs and regulate a sophisticated network of metabolic genes explains why in some cases CAR activation can have a similar protective role in liver injury. For example, Stedman et al. showed that both CAR and PXR influence cholesterol metabolism and bile acid synthesis by repressing and inducing the specific hepatic membrane transporters Oatpc (organic anion transporting polypeptide C) and Oatp2 (Na+-dependent organic anion transporter 2), respectively. This suggests their complementary roles as therapeutic targets for the treatment of cholestasis and lipid disorders. For reviews, please see 46, 47.

While PXR regulates drug clearance related genes, its expression is in turn regulated, indicative that xenobiotic metabolism is involved in other physiological events. Activation of the glucocorticoid receptor (GR) has been shown to induce expression of PXR, CAR and their heterodimeric partner RXR in cultured cells. In addition, in the rodent liver PXR expression is auto-induced by PCN and PPARα specific drugs such as perfluorodecanoic acid and clofibrate. Kamiya et al. also showed that HNF4α is the key transcription factor regulating responses to xenobiotics through activation of the PXR gene during fetal liver development. In theory, induction of the xenobiotic receptors could potentiate the
induction of downstream target genes. Therefore, some therapeutic drugs may be able to activate/induce PXR indirectly and influence liver injury. Further studies are expected to reveal the relevance of xenobiotic receptor regulation, and its impact on liver injury.

It is known that hPXR activators such as phenytoin and RU486 cause immunosuppressive side effects; on the other hand, inflammation and infection reduce hepatic CYP expression. In addition, the levels of hepatic PXR and CAR mRNA have also been reported to be downregulated in response to inflammatory signals. This broaches the question of whether xenobiotic receptors communicate with the immune system. Recently PXR has been reported to crosstalk with NF-κB signaling pathways, which regulate inflammation and the immune response. The activation of hPXR inhibits NF-κB activity whereas NF-κB target genes are upregulated and small bowel inflammation is significantly increased in PXR null mice. On the other hand, NF-κB activation reciprocally inhibits hPXR and its target genes. Therefore, PXR activators may act as better drugs for the treatment of chronic inflammatory liver diseases comparing to other non-PXR activator drugs.

In addition to its xenobiotic metabolism function, increasingly PXR is being seen as a regulator of hepatic damage. Further advancements in our understanding of the complexities of PXR's xeno/endobiotic regulation will advance PXR as a potential pharmaceutical target for healing both chronic and acute liver injuries.

Expert Opinion

Recent findings implicate PXR as a potential therapeutic target in acute liver injury. Importantly, PXR targeted therapies offer the potential to be tailored to the specific liver injury; PXR antagonists for APAP-induced ALI and PXR agonists for LPS-induced ALI (section 4). However, given the central role of PXR in liver xenobiotic and endobiotic metabolism, potential side effects of such therapies need to be thoroughly investigated (section 2.3), as well as possible patient variability in drug efficacy due to PXR gene polymorphisms.

The activation of xeno-receptors (PXR, CAR and AhR) in liver induces hepatic drug clearance enzymes including CYP3A, CYP2B, CYP2C, CYP1A UGT1A and MDR1. Importantly, the CYP3A family of enzymes involved in the metabolism of a large number of therapeutic drugs are regulated by PXR. Many drug-drug interactions have been attributed to PXR activation including the reduced effectiveness of oral contraceptives by St. John's wort, increased warfarin requirements when co-administered with rifampin, reduced serum levels and pharmacological effects of Cyclosporine A when combined with troglitazone treatment, and increased midazolam clearance after avasimibe administration. The recent studies implicating PXR activation in both chronic and acute liver injuries further emphasize its central role in xenobiotic metabolism. While testing of candidate drugs for PXR activity is not mandatory, performing such tests during the development phases may identify serious drug-drug interactions or unexpected liver diseases. Such testing should involve a combination of in vitro and in vivo assays incorporating humanized liver drug metabolism genes such as hCYP3A, hCYP2C and hUGT1A, and humanized PXR to more accurately predict possible drug-drug interactions and toxicity.
Personalized medicine will play an increasingly important role in modern medicine. Already, individual genetic information is used to predict disease susceptibility (e.g., BRCA1 and BRCA2 mutations and breast cancer\(^2\)), and has been associated with empirically determined drug dosages (e.g., warfarin treatments based on VKOR gene SNPs\(^3\)). The finding that particular PXR gene polymorphisms are associated with liver injury (section 5) suggests that, in the future, pharmacological dosing will also be determined based on the individual's genetic information. Already around 100 SNPs have been identified in the human PXR gene (UCSC Genome browser). The combination of increasingly lower costs for genome sequencing and an increase in pharmacogenetic studies on widely used drugs, will no doubt lead to additional PXR SNPs being associated with individual drug sensitivities and susceptibilities to a variety of liver diseases. We believe that the application of pharmacogenetics, in particular associating PXR gene polymorphisms with pharmaceutical drug pharmacokinetics, will form a significant part of modern personalized medicine.

**Acknowledgements**

The authors thank E. Ong and S. Ganley for administrative assistance. This work was supported, in part, by grants from NIH (ES10337), Ipsen/Biomeasure, The Helmsley Charitable Trust, Howard Hughes Medical Institute, and National Health and Medical Research Council of Australia Project grant 512354.

**Bibliography**

Papers of special note have been highlighted as either of interest

• or of considerable interest

•• to readers.


*Expert Opin Ther Targets. Author manuscript; available in PMC 2015 February 06.*


34. Schuetz EG, Brimer C, Schuetz JD. Environmental xenobiotics and the antihormones cyproterone acetate and spiranolactone use the nuclear hormone pregnenolone X receptor to activate the CYP3A23 hormone response element. Mol Pharmacol. 1998; 54:1113–7. [PubMed: 9855641]


40. Khurana S, Singh P. Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials. Liver Int. 2006; 26:943–8. [PubMed: 16953834] [Manuscripts 38 to 40 represent the early evidence that the activation of PXR’s protective role in chronic liver diseases.]


- PXR belongs to the nuclear receptor superfamily
- Transcriptional regulation by PXR plays important roles in hepatic xeno/endobiotic metabolism
- PXR affects chronic liver diseases
- Transcriptional activities of PXR implicated in acute liver injury
- PXR gene polymorphisms are associated with susceptibility to liver injury
Figure 1.
Model depicting the central role of the nuclear receptor PXR in the liver response to endobiotic and xenobiotic compounds. Activation of PXR by structurally and functionally diverse ligands induces the transcription of drug metabolizing enzymes and transporters. Compound modifications facilitate their removal (detoxicification), or conversely, increase their toxicity, resulting in systemic disorders such as endocrine disruption and chemo-resistance.